TY - JOUR
T1 - Hedgehog pathway inhibition in advanced basal cell carcinoma
T2 - Latest evidence and clinical usefulness
AU - Silapunt, Sirunya
AU - Chen, Leon
AU - Migden, Michael R.
N1 - Publisher Copyright:
© The Author(s), 2016.
PY - 2016/9/1
Y1 - 2016/9/1
N2 - Treatment of locally advanced basal cell carcinomas (laBCCs) with large, aggressive, destructive, and disfiguring tumors, or metastatic disease is challenging. Dysregulation of the Hedgehog (Hh) signaling pathway has been identified in the vast majority of basal cell carcinomas (BCCs). There are two United States Food and Drug Administration (US FDA)-approved Hh pathway inhibitors (HPIs) that exhibit antitumor activity in advanced BCC with an acceptable safety profile. Common adverse effects include muscle spasms, dysgeusia, alopecia, fatigue, nausea and weight loss.
AB - Treatment of locally advanced basal cell carcinomas (laBCCs) with large, aggressive, destructive, and disfiguring tumors, or metastatic disease is challenging. Dysregulation of the Hedgehog (Hh) signaling pathway has been identified in the vast majority of basal cell carcinomas (BCCs). There are two United States Food and Drug Administration (US FDA)-approved Hh pathway inhibitors (HPIs) that exhibit antitumor activity in advanced BCC with an acceptable safety profile. Common adverse effects include muscle spasms, dysgeusia, alopecia, fatigue, nausea and weight loss.
KW - Hedgehog pathway inhibitor
KW - basal cell carcinoma
KW - sonidegib
KW - vismodegib
UR - http://www.scopus.com/inward/record.url?scp=84981311874&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84981311874&partnerID=8YFLogxK
U2 - 10.1177/1758834016653605
DO - 10.1177/1758834016653605
M3 - Review article
C2 - 27583029
AN - SCOPUS:84981311874
SN - 1758-8340
VL - 8
SP - 375
EP - 382
JO - Therapeutic Advances in Medical Oncology
JF - Therapeutic Advances in Medical Oncology
IS - 5
ER -